Market Overview

BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke

Share:

Data Suggest That Targeted Intracerebral Delivery of Brain-Derived
Neurotrophic Factor Utilizing HyStem® Delivery Platform May Mitigate
Ischemic Brain Injury and Restore Functional Benefits

BioTime,
Inc.
(NYSE:BTX), a clinical-stage biotechnology company
focused on degenerative diseases, today announced the publication of
positive preclinical results which demonstrate that targeted
intracerebral delivery of brain-derived neurotrophic factor utilizing
HyStem®, BioTime's proprietary hydrogel delivery platform technology,
may mitigate ischemic brain injury and restore functional benefits by
reducing neuroinflammation. The article entitled, "Intracerebral
Delivery of Brain-Derived Neurotrophic Factor Using HyStem®-C Hydrogel
Implants Improves Functional Recovery and Reduces Neuroinflammation in a
Rat Model of Ischemic Stroke,"
was published in the International
Journal of Molecular Sciences
and is authored by clinicians at the Stanford
University School of Medicine
, Department of Neurosurgery.

"Results from this study, designed to simulate the clinical needs of
human stroke, underscore the ability of our proprietary HyStem® delivery
technology to target therapy dosing to a specific anatomical site such
as to the ischemic core, and minimize dissipation to surrounding
tissues," stated Francois Binette, SVP and Global Head of Product
Development at BioTime. "Brain-derived neurotrophic factor (BDNF) is
responsible for regulating neural stem cell differentiation and
survival, synapse development, and plays a key role in the
neuro-reparative processes that mediate cortical connectivity and
promote post-stroke recovery. In this model, utilizing our HyStem®
delivery platform, BDNF was shown over a three-week period to be
continuously released to the surrounding tissue, which could allow for
better long-term tissue and functional effects to occur compared to a
regular bolus injection."

Ischemic stroke is a leading cause of death and disability, and the
ischemic brain remains a difficult to reach anatomical target because of
the blood-brain barrier which limits availability of systemically
administered drugs. In order to reach therapeutic levels for neural
repair and functional recovery, many stroke therapies would have to be
administered at very high systemic doses because of the blood-brain
barrier, and therefore increasing risks of systemic or off-target side
effects. Implantable drug depots are being explored as a novel approach
for the delivery of treatments directly to the brain. BioTime's HyStem®
technology features a unique, biocompatible hydrogel designed to provide
a controlled-release drug depot and enable the effective delivery of
small and large biologic molecules.

In the published study, clinicians examined the effects of BDNF,
delivered via an extended release HyStem®-C hydrogel, on sensorimotor
function, infarct volume, and neuroinflammation, following permanent
distal middle cerebral artery occlusion (dMCAo) in rats. Improved
sensorimotor function was observed in rats treated with hydrogel +
BDNF(HIGH), particularly six to eight weeks following treatment
implantation. Infarct volume was reduced in rats treated with hydrogel +
BDNF(HIGH) as were levels of microglial, phagocyte, and astrocyte marker
immunoexpression in the corpus striatum. These data suggest that
targeted intracerebral delivery of BDNF using hydrogels may mitigate
ischemic brain injury and restore functional deficits by reducing
neuroinflammation.

About Stanford University School of Medicine, Department of
Neurosurgery

The Department of Neurosurgery at Stanford University School of Medicine
is a world leader in the fast-paced environment of innovative research
translation. The rich intellectual environment at Stanford, paired with
accessibility to the most advanced technology, is unmatched and ensures
the rapid translation of pioneering laboratory research into life-saving
clinical therapies for our patients. The Department of Neurosurgery
supports over 30 active labs investigating
everything from brain injury, deep brain stimulation, brain tumors,
epilepsy, pathophysiology and treatment of acute stroke, to the effects
of stress and aging on the nervous system. More information can be found online
or via Twitter at @TopNeuroDocs.

About HyStem®

HyStem® is BioTime's cell and drug delivery platform. HyStem® technology
includes a family of unique, biocompatible hydrogels designed to
effectively deliver cells or bioactive compositions for therapeutic
benefit. HyStem® was designed to enable the effective transfer,
engraftment and metabolic support for cells. The flexible chemistry of
the HyStem® also allows for hydrogel optimization in the delivery of
drugs and therapeutics. BioTime is actively pursuing local delivery
aspects of this platform technology.

About BioTime, Inc.

BioTime is a clinical-stage biotechnology company focused on the
development and commercialization of novel therapies for the treatment
of degenerative diseases. BioTime's pipeline is based on two platform
technologies which encompass cell replacement and cell/drug delivery.
BioTime's lead cell replacement product candidate is OpRegen®,
a retinal pigment epithelium transplant therapy in Phase 2 development
for the treatment of dry age-related macular degeneration, the leading
cause of blindness in the developed world. BioTime's lead cell delivery
clinical program is Renevia®, an investigational medical
device being developed as an alternative for whole adipose tissue
transfer procedures. BioTime common stock is traded on the NYSE American
and TASE under the symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter,
LinkedIn,
FacebookYouTube,
and Google+.
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company's email alert list: http://news.biotime.com.

Forward-Looking Statements

Certain statements contained in this release are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Any statements that are not historical fact
including, but not limited to statements that contain words such as
"will," "believes," "plans," "anticipates," "expects," "estimates"
should also be considered forward-looking statements. Forward-looking
statements involve risks and uncertainties. Actual results may differ
materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the business of BioTime, Inc. and its
subsidiaries, particularly those mentioned in the cautionary statements
found in more detail in the "Risk Factors" section of BioTime's Annual
Reports on Form 10-K and Quarterly Reports on Form 10-Q (copies of which
may be obtained at www.sec.gov).
Subsequent events and developments may cause these forward-looking
statements to change. BioTime specifically disclaims any obligation or
intention to update or revise these forward-looking statements as a
result of changed events or circumstances that occur after the date of
this release, except as required by applicable law.

View Comments and Join the Discussion!